ePrints

Light-activated antibodies in the fight against primary and metastatic cancer

Lookup NU author(s): Dr Stephen Thompson, Emeritus Professor Colin Self

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The very cytotoxic potency of therapeutic antibodies used in the fight against cancer makes their specific tumour targeting of crucial importance. Unfortunately, in practice, this is often not achieved and can lead to dangerous side-effects. A way of greatly reducing such side-effects is to make the antibodies region-specific to the areas bearing tumour. This can now be achieved by rendering them light dependent so they are only active where illuminated. There are many ways of employing such light-enhanced targeting in very many locations within the body. When it is applied to direct killer T-cells to ovarian primary tumours, not only is primary tumour growth markedly reduced but also a dramatic reduction of metastatic growth is observed in the liver.

Publication metadata

Author(s): Thompson S, Self AC, Self CH

Publication type: Review

Publication status: Published

Journal: Drug Discovery Today

Year: 2010

Volume: 15

Issue: 11-12

Pages: 468-473

Print publication date: 05/05/2010

ISSN (print): 1359-6446

ISSN (electronic): 1878-5832

Publisher: ELSEVIER SCI LTD

URL: http://dx.doi.org/10.1016/j.drudis.2010.04.006

DOI: 10.1016/j.drudis.2010.04.006

Share